In the future, combined blockade of the STAT1/ETS1 regulatory axis with immune checkpoint inhibitors, or combined with EGFR-TKI targeted therapy, is expected to break the treatment bottleneck of EGFR/TP53 co-mutated NSCLC and improve patients’ response rate to immunotherapy and overall survival benefits. This evidence concerns the gene TP53 and non-small cell lung carcinoma.